Synovial sarcoma is a malignant soft tissue tumor that most commonly occurs in the extremities of young and middle-aged adults, in the vicinity of large joints. Although synovial sarcoma is frequently associated with joints, it may arise in unexpected sites, such as the mediastinum, heart, lung, pleura, or chest wall. Primary synovial sarcoma of the pleura is rare. To date, nearly 36 cases of primary synovial sarcoma of the pleura have been reported since Gaertner et al. published the first case in 1996. The oncologic characteristics, treatment, and prognosis for pleural synovial sarcomas are not well defined because of a paucity of data. However, a multimodal approach, including surgical resection, chemotherapy, and radiotherapy, has generally been suggested. We report the outcome of one patient with primary pleural synovial sarcoma treated with radical resection and adjuvant treatment. The specific chromosomal translocation (X:18) is found in more than 90% of synovial sarcomas and can be detected by the fluorescence in-situ hybridization method [4] . Synovial sarcoma encompasses two histologic subtypes: monophasic and biphasic. The presence of poorly differentiated tumor cells within lesions of either subtype is considered to be a poor prognostic factor [5] . In this report, the tumor was a poorly differentiated monophasic synovial sarcoma. In general, treatment for soft tissue sarcoma comprises a combination of surgical resection, radiotherapy, and chemotherapy [6] .
Although there is no gold standard of treatment for primary pleural synovial sarcoma, a multidisciplinary approach, including surgical resection, chemotherapy, and radiotherapy has been suggested. Radical resection is the mainstay of treatment. Adjuvant radiotherapy is usually recommended in cases of incomplete resection or extensive resection of a large tumor [7] . The benefits of chemotherapy are unclear. However, neoadjuvant chemotherapy can be beneficial prior to radical resection since it can cause reduction in tumor volume and potentially treat micrometastasis [8] . The 5-year survival rate for synovial sarcoma is 50% to 80%, depending on the patient's age, the tumor size, and its resectability [9] . The primary synovial sarcoma of the chest has a high recurrence rate. Duran-Mendicuti et al. [10] reported that the disease-free interval was 2 to 14 months after surgical resection of primary pleural synovial sarcoma. Because a synovial sarcoma of the pleura is rare, data regarding its natural history and published cases are limited. In our medical center, radical resection was performed for synovial sarcoma arising in the parietal pleura. After radical resection, adjuvant radiotherapy was performed. In conclusion, further investigation and data collection are required to optimize treatment for primary synovial sarcoma of the pleura.
